Answers are grounded in this paper and cite their sources.
Purpose Markedly elevated lactate dehydrogenase (LDH) occurs in various pediatric conditions, but its association with malignancy remains poorly characterized. We aimed to characterize associated diagnoses and evaluate the relationship between LDH elevation and malignancy alongside clinical and laboratory findings. Methods We retrospectively studied children aged 0–18 years hospitalized through the emergency department at a tertiary pediatric center between 2012 and 2022 with LDH ≥ 1,500 U/L (≥ 3 times the upper limit of normal). Associations between malignancy and LDH levels, age, complete blood count (CBC) abnormalities, and clinical features were evaluated using odds ratios across cumulative LDH thresholds. Multinomial logistic regression estimated malignancy probabilities across continuous LDH levels. Results Among 1,226 children, infection was the most common diagnosis (48%), followed by malignancy (18%; 13% hematologic, 5% solid). Malignancy accounted for 10% of patients with LDH 1,500–2,500 U/L, 46% with LDH > 2,500 U/L, and 53% with LDH > 5,000 U/L. Malignancy increased with age, from 6% among infants to 38% among children and 39% among adolescents. Among patients with CBC abnormalities, 28% had malignancy, compared with 2% without abnormalities. Of patients with malignancy, 94% had at least one CBC abnormality. Conclusion Higher LDH levels were associated with increased likelihood of malignancy, although infection remained the most common diagnosis. Markedly elevated LDH should prompt clinical reassessment and consideration of malignancy alongside other findings.
No takes yet. Share an insight, caveat, or question.
Tausky et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: